{
  "id": 17381706,
  "title": "Gym bros love BPC-157, the peptide in the 'Wolverine shot.' Now it could go mainstream.",
  "url": "https://urgent.news/2026/10/31/gym-bros-love-bpc-157-the-peptide-in-the-wolverine-shot-now-it-could",
  "topic": "business",
  "section": "Business",
  "published": "2026-10-31T10:00:01.000Z",
  "source": {
    "name": "Business Insider",
    "slug": "business-insider",
    "url": "https://www.businessinsider.com/bpc-157-wolverine-shot-recovery-peptide-boom-2026-10"
  },
  "original_language": "en",
  "account": "BPC-157, a peptide popular among fitness and biohacking enthusiasts, has gained significant attention for its potential to accelerate injury healing. This peptide, short for \"body protection compound,\" is derived from human gastric juice and has shown promise in animal studies for promoting tissue repair. Despite its growing popularity, particularly in the form of the \"Wolverine shot\" that combines BPC-157 with TB-500, there is a lack of rigorous human evidence regarding its safety and effectiveness.\n\nThe potential for BPC-157 to become more mainstream has been bolstered by a new policy announced by the Trump administration. The policy aims to allow broader access to peptides like BPC-157, provided that certain conditions are met, such as pharmacies meeting specific criteria when compounding and selling these substances to patients. This change could offer a more regulated alternative to the uncontrolled sellers currently dominating the market.\n\nRobert F. Kennedy Jr.'s Department of Health and Human Services has taken steps to ease regulation on BPC-157, along with five other peptides that have gained popularity among gym enthusiasts. These peptides have garnered significant interest due to their alleged ability to enhance healing and longevity, although most claims are based on animal studies with limited data on human safety and efficacy.\n\nThe proposed clinical trial, which is scheduled to begin in the summer of 2027, will involve 20 patients recovering from shoulder surgery. The trial, which will be randomized, double-blind, and placebo-controlled, aims to assess the safety and effectiveness of BPC-157 in humans. The principal investigator, Dr. Shiloah Kviatkovsky, is an assistant professor of orthopedic surgery at the University of Arkansas for Medical Sciences. She stated that the trial will provide a more rigorous evaluation of BPC-157's potential benefits and risks compared to anecdotal evidence found on social media.\n\nDespite the growing interest in BPC-157, the lack of rigorous human research poses significant challenges. The peptide can be purchased on the gray market, where it may be contaminated, inconsistently dosed, or entirely counterfeit. This lack of oversight and regulation raises concerns about the safety and efficacy of the peptide when used outside of controlled clinical settings. As the debate continues, researchers and enthusiasts alike await the results of the upcoming clinical trial to determine whether BPC-157 lives up to its hype.",
  "summary": "Trump's HHS has eased restrictions on BPC-157, a buzzy recovery peptide in the \"Wolverine shot.\" But human evidence is scant.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}